Dyadic DYAI 深 滬
等待開盤 11-04 09:30:00 美东时间
0.36
-0.016
-4.26%
華盛通- 最 高0.3728
- 今 開0.3611
- 成交量 4.95万股
- 最 低 0.36
- 昨 收 0.376
- 總市值 1442.29万
- 52周最高 1.60
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 0.3401
- 委 比 -60.15%
- 總股本 4006.37万
- 歷史最高 10.98
- 量 比 0.59
- 振 幅 3.40%
- 歷史最低 0.3401
- 每 手 1
- 風險率 0.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
Dyadic International announced it will report its Q3 2026 financial results and host a corporate update conference call on November 12, 2026, at 5:00 p.m. ET. The call will be accessible via dial-in numbers +1-877-407-9219 or +1 412-652-1274 (conference ID: 13761286) or a live webcast. A replay will be available on the company's website. Questions for the Q&A session can be submitted to jlavalley@dyadic.com in advance. Dyadic is a global biotech ...
10-30 20:05
Dyadic International shares are trading lower after the company reported worse-than-expected Q2 financial results.
Dyadic International shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-13 00:32
Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate
Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is unchanged from the same period last year. The company reported quarterly sales of $961.138 thousand which missed the analyst consensus estim...
08-12 20:38
Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins
Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its com...
08-04 19:27
Dyadic International Regains Nasdaq Compliance
Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confir...
07-24 19:30
Dyadic Announces Continued Listing on the Nasdaq Capital Market
Dyadic International has regained compliance with Nasdaq listing rules, ensuring its stock remains listed on the Nasdaq Capital Market. CEO Mark Emalfarb expressed satisfaction with this development and emphasized the company's focus on advancing its business strategy, including product development, platform expansion, and collaborations. Dyadic specializes in scalable, non-animal protein production platforms for various industries, utilizing its...
07-24 11:30
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
Dyadic International announced the expansion of its bio-industrial pipeline with a new proprietary enzyme program for advanced cellulose processing, building on the success of EN3ZYME™ and demonstrating the scalability of its Dapibus™ platform. The program targets applications like pulp biorefining and cellulose production, addressing a multi-billion-dollar market for sustainable industrial enzyme solutions. Dyadic plans to commercialize the enzy...
07-16 12:00
Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces Heterothallica Recombinant Protein Expression Technology
The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant protection to the Company’s expanding global intellectual property portfolio and reinforces the strength of...
06-29 19:27
Dyadic Expands IP Protection and Business Development Activities in Japan
Dyadic International announced that the Japan Patent Office has approved claims for its proprietary *Thermothelomyces heterothallica* recombinant protein expression technology, strengthening its intellectual property portfolio and strategic platforms. The company, which focuses on scalable microbial protein production, is expanding its presence in Japan through collaborations with Intralink, targeting key sectors like biotechnology, pharmaceutica...
06-29 11:25
